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Introduction
According to Globocan 2018, there were reported 
2 088 849 of new cases of breast cancer (11.2% incidence), 
being the most frequent neoplasia in women and the lead-
ing cause of female cancer related death [1].
Treatment strategy depends on tumor progression and 
its morphological type. Molecular classification, based on 
the evaluation of estrogen receptor (ER), progesterone re-
ceptor (PR), human epidermal growth factor receptor 2 
(HER2), cytokeratin 5 (CK5) and epidermal growth factor 
receptor (EGFR), includes Luminal A, B, HER2 and triple-
negative subtypes. This classification had a huge impact on 
individual prognosis, personalized treatment and response 
to the therapy. Despite the fact that many things about 
breast cancer have been discovered there are still a lot of 
questions. Molecular classification does not comprise and 
does not describe perfectly all of the entities, that’s why new 
molecular markers must be identified. These could reveal 
new information about tumorigenesis [2, 3].
Cancer research was focused on the studying of prop-
er tumor cells for a long time. But cancer cells do not act 
alone, tumor consists of both malignant and non-malignant 
elements like macrophages, lymphocytes, mast cells, fibrob-
lasts, connective tissue fibers, nerve fibers. Among these, 
tumor associated macrophages represent the vast majority, 
sometimes more than 50%. Their importance should not be 
underestimated because they are able to control the immune 
response, cellular mobility and to stimulate/inhibit angio-
genesis and lymphangiogenesis. Moreover, macrophages 
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Abstract
Background: Cancer research was focused on the studying of proper tumor cells for a long time. Despite the huge progress, there are still a lot of questions, 
that’s why new molecular markers must be identified. These could reveal new information about tumorigenesis. 
Material and methods: 15 cases of ductal invasive breast carcinomas have been analyzed and researched on tumor associated macrophages via 
immunohistochemistry. CD68 was used as a macrophage marker and CD68+ cells were evaluated in tumor nest and peritumoral area, as well as hormone 
receptors (ER, PR) and HER2 protein.
Results: Most of tumors (10 cases out of 15/ 66.7%) were moderately differentiated (G2). The mean and std. error of mean of intratumoral CD68+ cells 
were 2.0±0.2, of peritumoral CD68+ cells – 1.4±0.2. Intratumoral CD68+ cells registered higher scores than those located in the peritumoral area.
Conclusions: CD68+ cells are more likely to be present in the tumor nest rather than in the peritumoral area. This research did not establish any significant 
correlations between intratumoral and peritumoral CD68+ cells and patients’ age, tumor grade, expression of ER and PR. The content of peritumoral 
CD68+ cells inversely correlated with the number of HER2+ carcinoma cells.
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can modulate the drug resistance by various substances se-
creted into the microenvironment [4, 5]. 
Macrophages can be differentiated into 2 types depend-
ing on the chemical signals coming from the microenvi-
ronment: classically activated macrophages (M1) and al-
ternatively activated macrophages (M2). M1 macrophages 
exhibit antitumoral activity because of their ability to acti-
vate type 1 helper T cells (Th1), recognize the cancer cells 
and phagocytose them. M2 macrophages on the other hand 
are involved in wound healing where they downregulate 
the inflammatory reactions, promote angiogenesis, recruit 
fibroblasts and regulate connective tissue remodeling. Thus, 
an increased number of M1 macrophages is associated with 
a lower tumor aggressiveness, whereas an increased number 
of M2 macrophages stimulates tumor growing and involves 
a poor prognosis [5, 6, 7]. 
The aim of this study was to determine the role of tumor 
associated macrophages in breast cancer pathology. We also 
researched on the localization of the macrophages (tumor 
nest/ peritumoral area) by studying the expression of CD68 
marker and identified whether there does exist any correla-
tion between CD68+ cells and ER+, PR+, HER2+ carcinoma 
cells. As a result, a single statistically significant negative 
correlation between CD68+ cells and HER2+ cells was estab-
lished.
Material and methods
This research included 15 cases of ductal invasive breast 
carcinomas type NOS (not otherwise specified) collected 
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at Arad Clinical Hospital, Romania between 2013-2016. 
Patients ranged between 60 and 83 years old, mean of age 
being 69.6±2.1. All patients did not undergo chemo- or ra-
diotherapy before surgery. The study was approved by the 
Ethics Committee of Nicolae Testemitsanu State University 
of Medicine and Pharmacy, Chisinau, Moldova (no. 33/ 37/ 
12.02.2018). 
Histological method.  Specimens were obtained after 
surgery and fixed in 10% formalin. After the removal of 
fixative by washing with tap water, specimens were paraffin 
embedded (Paraplast High Melt, Leica Biosystems). Paraffin 
blocks were later used for creation of tissue microarrays by 
means of TMA Grand Master (3DHISTECH Ltd., Budapest, 
Hungary). Sections from these blocks were cut by using a 
Leica RM2245 microtome (Leica Biosystems, Newcastle 
UponTyne, UK) and mounted on glass slides (Surgipath X-
tra Adhesive, Leica Biosystems, Newcastle UponTyne, UK).
Staining was accomplished by Leica Autostainer XL 
(Leica Biosystems, Newcastle UponTyne, UK). Mayer’s he-
matoxylin (Merck, Germany) and aqueous eosin (Merck, 
Germany) were used. Slides were mounted automatically 
(Leica CV5030, Leica Biosystems, Newcastle UponTyne, 
UK). Tumor histology was reviewed by 3 pathologists and 
appropriate sections were selected for immunohistochemi-
cal stains. 
Immunohistochemistry.  Immunohistochemical stain-
ing was performed automatically by Leica Bond-Max (Leica 
Biosystems, Newcastle UponTyne, UK). Antigen retrieval 
was achieved by using of Bond Epitope Retrieval Solution 
1 (pH 6) and 2 (pH 9) (Leica Biosystems, Newcastle Upon-
Tyne, UK). Primary antibody (ER, PR, HER2, CD68) was 
followed by 3% hydrogen peroxide (for endogenous peroxi-
dase activity blocking). DAB (3, 3’- diaminobenzidine) was 
applied as a chromogen substrate for 10 minutes. Mayer’s 
hematoxylin was the additional dye used for counterstaining 
(5 minutes). Then sections were placed in absolute alcohol 
for 5 minutes, dried and clarified in benzene for 5 minutes. 
Lastly, slides were mounted automatically (Leica CV5030, 
Leica Biosystems, Newcastle UponTyne, UK) using an EN-
TELLAN–like mounting medium (Leica CV Mount, Leica 
Biosystems, Newcastle UponTyne, UK) [8]. 
Methods of quantification.  Hormone receptors (ER 
and PR) were evaluated according to Allred score. This 
score accounts the percentage of cells that test positive for 
hormone receptors, along with the intensity of staining [9]. 
HER2 protein was appreciated according to the recommen-
dations of American Society of Clinical Oncology [10, 11]. 
CD68 is a glycoprotein found in lysosomes and to a 
lesser extent on the cell membrane. It is used for identifica-
tion of macrophages, other members of the mononuclear 
phagocyte lineage and to describe the neoplasm of myeloid 
and macrophage/monocyte origin. Macrophages should 
show a moderate to strong cytoplasmic staining reaction 
[2, 12]. Quantification of brown stained macrophages was 
done by means of Axio Imager A2 microscope (Carl Zeiss, 
Germany). Sections were initially analyzed at a ×100 mag-
nification in order to determine the most intensely stained 
regions. Then we analyzed intratumoral and peritumoral 
stroma, 2 microscopic fields for each one, at a ×200 magni-
fication. The following score was applied: “0” – no staining 
observed; “+1” – up to 25% of CD68+ cells; “+2” – 25-75% 
CD68+ cells; “+3” – more than 75% CD68+ cells. “+1”, “+2” 
and “+3” were considered positive scores. The final value 
was the arithmetic mean of the values for the two fields. 
Data analysis.  A MS Excel 2010 database was used to 
store the data that were statistically analyzed by applying 
WinSTAT software.  We considered a p-value of less than 
0.05 as significant. 
Results
Most of tumors (10 cases out of 15/66.7%) were mode-
rately differentiated (G2). The other 5 cases (33.3%) were 
poorly differentiated (G3). 
The mean and std. error of mean of ER+ cells were 
1.9±0.2; of PR+ cells – 0.9±0.2; of HER2+ cells – 0.5±0.2. 
Median’s values were: “2” for ER, “1” for PR, “0” for HER2 
(tab. 1).
Table 1
Patients’ age, tumor grade, values of ER, PR, HER2, 
CD68+ cells
  Age Grade ER PR HER2 CD68it CD68pt
Valid cases 15 15 15 15 15 15 15
Mean 69.6 2.3 1.9 0.9 0.5 2.0 1.4
 m 2.1 0.1 0.2 0.2 0.2 0.2 0.2
Minimum 60 2 0 0 0 0 1
Maximum 83 3 3 2 2 3 3
Median 67 2 2 1 0 2 1
Note: CD68it – intratumoral CD68+ cells; CD68pt – peritumoral CD68+ 
cells; m – Std. error of mean.
Table 2
The comparative analysis of patients’ age,  
tumor grade and molecular markers
Age Grade ER PR HER2 CD68it CD68pt
Age
rs   0.31 0.26 0.09 -0.06 0.22 -0.02
P   0.13 0.18 0.38 0.42 0.22 0.47
Grade
rs 0.31   0.19 -0.30 0.00 0.40 -0.19
P 0.13   0.25 0.14 0.50 0.07 0.25
ER
rs 0.26 0.19   0.39 0.32 0.18 -0.30
P 0.,18 0.25   0.07 0.12 0.25 0.14
PR
rs 0.,09 -0.30 0.39   0.42 0.23 -0.24
P 0.38 0.14 0.07   0.06 0.20 0.20
25
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HER2
rs -0.06 0.00 0.32 0.42   -0.25 -0.53
P 0.42 0.50 0.12 0.06   0.19 0.02
CD68it
rs 0.22 0.40 0.18 0.23 -0.25   0.33
P 0.,22 0.,07 0.25 0.20 0.19   0.11
CD68pt
rs -0.02 -0.19 -0.30 -0.24 -0.53 0.33  
P 0.47 0.25 0.14 0.20 0.02 0.11  
Note: Age – patients’ age; Grade – tumor grade; ER – estrogen receptor; 
PR – progesterone receptor; HER2 – human epidermal growth factor 
receptor 2; CD68it – intratumoral CD68+ cells; CD68pt – peritumoral 
CD68+ cells; rs – Spearman rank correlation; p – statistical significance. 
Statistically significant cases were marked in bold.
The mean and std. error of mean of intratumoral CD68+ 
cells were 2.0±0.2; median was “2”. In case of peritumoral 
CD68+ cells, the mean and std. error of mean were 1.4±0.2; 
median was “1”. Intratumoral CD68+ cells registered higher 
scores than those located in the peritumoral area. 
The comparative analysis of intratumoral, peritumoral 
CD68+ cells and molecular markers (ER, PR, HER2) re-
vealed a single statistically significant negative correlation 
between the expression of HER2 protein and peritumoral 
CD68+ cells (rs = -0.53, p<0.02), (tab. 2).
Discussion
Breast cancer is a heterogeneous disease in terms of 
histology,  therapeutic response, dissemination patterns to 
distant sites, and patients’ outcomes. A plausible explana-
tion for this scenario is, in part, that we still lack a com-
plete picture of the biologic heterogeneity of breast cancers 
with respect to molecular alterations, treatment sensitivity, 
and cellular composition. Importantly, this complexity is 
not entirely reflected by the main clinical parameters (age, 
node status, tumor size, histological grade) and pathological 
markers (ER, PR and HER2), all of which are routinely used 
in the clinic to stratify patients for prognostic predictions 
and to select treatments [13]. In this study we partially ap-
proached macrophages, just one actor of this complex sce-
nario. 
CD68 is a pan-macrophage marker used as a marker 
for tumor associated macrophages. However, CD68 recog-
nizes both tumoricidal M1 (classically activated) and anti-
inflammatory M2 (alternatively activated) macrophages 
[5]. The term of macrophage activation was introduced by 
Mackaness in the 1960s in an infection context to describe 
the antigen-dependent, but non-specific enhanced, micro-
bicidal activity of macrophages toward BCG (bacillus Cal-
mette-Guerin) and Listeria upon secondary exposure to the 
pathogens [14]. M1 macrophages, or classically activated 
macrophages, are aggressive and highly phagocytic, pro-
duce large amounts of reactive oxygen and nitrogen species, 
and promote a Th1 response [11]. This is a macrophage re-
sponse usually seen during microbial infections. M1 macro-
phages secrete high levels of IL-12 and IL-23, two important 
inflammatory cytokines. IL-12 induces the activation and 
clonal expansion of Th17 cells, which secrete high amounts 
of IL-17, and thus contribute to inflammation. In the con-
text of cancer, classically activated macrophages are thought 
to play an important role in the recognition and destruction 
of cancer cells, and their presence usually indicates good 
prognosis. For a long time, M1 macrophages were thought 
to be the only functional macrophages and that anti-inflam-
matory molecules were inhibitory to their function. Now 
we understand that anti-inflammatory molecules did not 
inhibit macrophage function but provided an alternative ac-
tivation of macrophages. M2 macrophages, or alternatively 
activated macrophages, are anti-inflammatory and are not 
capable of efficient antigen presentation. Expression of IL-
10 by M2 macrophages promotes a Th2 response, and Th2 
cells, in turn, upregulate the production of IL-3 and IL-4. 
IL-4 is an important cytokine in the healing process because 
it contributes to the production of the extracellular matrix. 
The tumor microenvironment significantly affects macro-
phage polarization. The process of polarization can be di-
verse and complicated because of the complex environment 
of IL-10, glucocorticoid hormones, apoptotic cells, and im-
mune complexes that can interfere with the function of in-
nate immune cells [15].
According to Weagel et al., the tumor mass contains a 
great number of M2-like macrophages and these can be 
used as a target for cancer treatment. Reducing the number 
of M2s or polarizing them towards an M1 phenotype can 
help destroy cancer cells or impair tumor growth [15]. Un-
fortunately, our study did not reveal which macrophages 
have registered higher scores in the intratumoral area: M1s, 
being able to destroy the tumor or maybe M2 macrophages, 
promoting tumor growth and repair?
CD163 could be the answer to our questions. CD163 is a 
scavenger receptor upregulated by macrophages in an anti-
inflammatory environment and regarded as a highly spe-
cific monocyte/macrophage marker for M2 macrophages. 
This research could be continued by studying the specific 
M1 and M2 macrophages’ markers, the localization of cells 
rather than merely the presence of tumor associated macro-
phages [6]. Results must be confirmed in a higher number 
of cases. 
Conclusions
CD68+ cells are more likely to be present in the tumor 
nest rather than in the peritumoral area. This research did 
not establish any significant correlations between intratu-
moral and peritumoral CD68+ cells and patients’ age, tumor 
grade, expression of ER and PR. The content of peritumoral 
CD68+ cells inversely correlate with the number of HER2+ 
carcinoma cells. 
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